Literature DB >> 31160330

RAS Mutations Are Not Created Equal.

G Aaron Hobbs1, Channing J Der2,3.   

Abstract

In this issue of Cancer Discovery, Poulin and colleagues apply structural, biochemical, and biological profiling of two mutants of KRAS, one found most frequently in all cancers (G12D) and one found nearly exclusively in colorectal cancer (A146T). They provide compelling evidence that specific mutations will impart different structural and biochemical consequences on KRAS function and that the same KRAS mutation displays tissue-distinct signaling and biological consequences.See related article by Poulin et al., p. 738. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31160330     DOI: 10.1158/2159-8290.CD-19-0406

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  8 in total

1.  KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K-MAPK1 inhibition.

Authors:  Harish Palleti Janardhan; Xiuling Meng; Karen Dresser; Lloyd Hutchinson; Chinmay M Trivedi
Journal:  J Exp Med       Date:  2020-07-06       Impact factor: 14.307

2.  Proteomics reveals a therapeutic vulnerability via the combined blockade of APE1 and autophagy in lung cancer A549 cells.

Authors:  Shu-Ting Pan; Ji Zhou; Fang Yang; Shu-Feng Zhou; Tao Ren
Journal:  BMC Cancer       Date:  2020-07-08       Impact factor: 4.430

Review 3.  Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.

Authors:  Kinga Nyíri; Gergely Koppány; Beáta G Vértessy
Journal:  Cancer Metastasis Rev       Date:  2020-12       Impact factor: 9.264

Review 4.  The Ins and Outs of RAS Effector Complexes.

Authors:  Christina Kiel; David Matallanas; Walter Kolch
Journal:  Biomolecules       Date:  2021-02-07

5.  Enhanced interpretation of 935 hotspot and non-hotspot RAS variants using evidence-based structural bioinformatics.

Authors:  Swarnendu Tripathi; Nikita R Dsouza; Angela J Mathison; Elise Leverence; Raul Urrutia; Michael T Zimmermann
Journal:  Comput Struct Biotechnol J       Date:  2021-12-11       Impact factor: 7.271

6.  Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.

Authors:  Dan Zhao; Haiqing Li; Isa Mambetsariev; Tamara Mirzapoiazova; Chen Chen; Jeremy Fricke; Prakash Kulkarni; Victoria Villaflor; Leonidas Arvanitis; Stanley Hamilton; Michelle Afkhami; Raju Pillai; Brian Armstrong; Loretta Erhunmwunsee; Erminia Massarelli; Martin Sattler; Arya Amini; Ravi Salgia
Journal:  Cancers (Basel)       Date:  2022-10-08       Impact factor: 6.575

Review 7.  The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy.

Authors:  Jimin Yuan; Xiaoduo Dong; Jiajun Yap; Jiancheng Hu
Journal:  J Hematol Oncol       Date:  2020-08-17       Impact factor: 17.388

Review 8.  Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy.

Authors:  Ufuk Degirmenci; Mei Wang; Jiancheng Hu
Journal:  Cells       Date:  2020-01-13       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.